Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma

Clinical trial NCT06728618 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06728618
Sponsor: Shanghai Zhongshan Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Oral Squamous Cell Carcinoma (OSCC)Oropharyngeal Squamous Cell Carcinoma (SCC)Resectable Oral and Oropharyngeal Squamous Cell Carcinoma Recurrent Oral and Oropharyngeal Squamous Cell Carcinoma

Start date: 2024-12-01
Primary completion: 2026-05-01
Enrollment: 28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.